menu
    • menu
    [{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inkef Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cardior Pharmaceuticals \/ Inkef Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inkef Capital"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1100000000000001,"dosageForm":"Injection","sponsorNew":"Cardior Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Novo Nordisk"}]

    Find Clinical Drug Pipeline Developments & Deals by Cardior Pharmaceuticals

    Menu

    Cardior Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Novo Nordisk

                            Deal Size : $1,110.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novo Nordisk to Acquire Cardior Pharmaceuticals, Enhancing Its Cardiovascular Pipeline

                            Details : Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for heart failure.

                            Brand Name : CDR132L

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 25, 2024

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Novo Nordisk

                            Deal Size : $1,110.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based ...

                            Details : CDR132L is synthetic antisense oligonucleotide-based inhibitor directed against microRNA-132, that up-regulated in cardiac tissue of heart failure patients leading to expression of genes that are crucially involved in cardiac function thus leading to pat...

                            Brand Name : CDR132L

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 20, 2022

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inkef Capital

                            Deal Size : $76.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

                            Details : The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.

                            Brand Name : CDR132L

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 25, 2021

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inkef Capital

                            Deal Size : $76.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure...

                            Details : The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.

                            Brand Name : CDR132L

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 29, 2021

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardior Pharmaceuticals' CDR132 Demonstrates Improvement of Heart Function in Chronic Heart Failure Model

                            Details : The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.

                            Brand Name : CDR132L

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 22, 2020

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Cardior Pharmaceuticals

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L

                            Details : In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            January 31, 2020

                            Lead Product(s) : CDR132L

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth